1. Home
  2. TBPH vs ERII Comparison

TBPH vs ERII Comparison

Compare TBPH & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.86

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Energy Recovery Inc.

ERII

Energy Recovery Inc.

HOLD

Current Price

$9.93

Market Cap

850.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
ERII
Founded
2013
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
850.2M
IPO Year
2013
2008

Fundamental Metrics

Financial Performance
Metric
TBPH
ERII
Price
$13.86
$9.93
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$18.50
$16.50
AVG Volume (30 Days)
782.6K
783.4K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.00
EPS
0.88
0.42
Revenue
$15,386,000.00
$134,987,000.00
Revenue This Year
$70.90
$17.21
Revenue Next Year
N/A
$21.97
P/E Ratio
$15.75
$23.64
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$9.59
52 Week High
$21.03
$18.31

Technical Indicators

Market Signals
Indicator
TBPH
ERII
Relative Strength Index (RSI) 27.74 25.07
Support Level $13.41 $9.59
Resistance Level $14.76 $14.85
Average True Range (ATR) 0.58 0.49
MACD -0.08 -0.08
Stochastic Oscillator 11.29 15.84

Price Performance

Historical Comparison
TBPH
ERII

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About ERII Energy Recovery Inc.

Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.

Share on Social Networks: